Virtual ACC 2020 | PARTNER 3: TAVR vs CABG in Low Risk at 2 Years

The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a numerical benefit in favor of transcatheter aortic valve replacement (TAVR) vs. surgical replacement (CABG) for the primary end point of death, stroke or repeat hospitalization for cardiovascular reasons. However, the initially higher advantage of TAVR has been narrowing down because of an uptick in deaths and strokes. 

When the PARTNER 3 was presented just one year ago for the same ACC event, the difference between these treatments was 7.1%, which was enough to show not just non-inferiority of TAVR vs. CABG, but also superiority. After the virtual presentation of the PARTNER 3 2-year outcomes at the virtual ACC 2020, we observe the difference between both treatments has shrunk to 5.9%, which is still enough to show non-inferiority.

Whether the curves will keep separate, even by a small margin, or not, they continue to follow this trend and end up crossing at some point, this is mere speculation, according to M. Mack himself, who presented the outcomes. 

The PARTNER 3 included 1000 patients with an STS of 4% or lower (mean STS 1.9%) treated with the balloon expandable Sapien 3 or CABG in 71 different centers. 


Read also: Virtual ACC 2020 | Antidote for Life-Threatening Bleeding with New Anticoagulant Agents.


At 2 years, TAVR maintains its difference compared against CABG for the combined end point (11.5% vs 17.4%; HR 0.63, 0.45 to 0.88) but not for the individual components (except for repeat hospitalizations).

The main reason behind rehospitalizations in both groups was cardiac failure.

The TAVR group presented a lower incidence of atrial fibrillation (7.9% vs 41.8%) and more new left bundle branch block (24.4% vs 9.4%; p<0.001). Valve thrombosis (VARC 2 definition) was more frequent in the TAVR group (2.6% vs 0.7%; p=0.02).

The echo test at 2 years did not show changes in mean gradient compared to prior levels (13.6 vs 11.8 mmHg; p<0.001), valve area (1.7 vs 1.7 cm2; p=0.69) or paravalvular regurgitation (p<0.001). 

Original Title: Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial.

Reference: Mack MJ et al. Presentado en forma virtual en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

IVUS Assessment in Patients at High Risk of Coronary Occlusion After TAVI: Results from the ICARO Study

Courtesy of Dr. Juan Manuel Pérez. Acute coronary obstruction (ACO) is a rare but potentially fatal complication following transcatheter aortic valve implantation (TAVI), particularly in...

Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing...

Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes

Tricuspid regurgitation (TR) has been associated with increased mortality and functional deterioration. Even though the current guidelines recommend tricuspid valve surgery, supporting evidence is...

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

Researchers analyzed a total of 1062 patients who underwent transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation (TR). Risk was classified using the TRI-SCORE: low (0–3...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Watchman FLX and Improvement Impact vs. 2.5

Left atrial appendage occlusion (LAAO) represents an effective alternative to oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation at high risk of thromboembolic...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...